AbbVie Inc. (FRA:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 286.84B |
| Revenue (ttm) | 53.08B |
| Net Income (ttm) | 3.84B |
| Shares Out | n/a |
| EPS (ttm) | 2.16 |
| PE Ratio | 74.62 |
| Forward PE | 15.18 |
| Dividend | 5.86 (3.58%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 9 |
| Average Volume | 101 |
| Open | 164.80 |
| Previous Close | 164.80 |
| Day's Range | 164.60 - 164.80 |
| 52-Week Range | 147.00 - 203.05 |
| Beta | n/a |
| RSI | 53.79 |
| Earnings Date | Jul 25, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on high...
Why AbbVie Is a Strong Buy for Long-Term Investors in 2025
AbbVie Inc. (ABBV) has emerged as a strong performer in financial and technical terms, attracting investor attention due to its long-term growth potential. With consistent revenue generation and expan...
AbbVie: Why I Set A $175 Buy Order
Nomura remains neutral on Glenmark, says near-term upside for stock captured post ISB-2001 deal
Nomura has reiterated its ‘Neutral’ rating on Glenmark Pharmaceuticals, maintaining a target price of ₹1,500. This comes after the company held its post-earnings analyst meeting, where management comm...
My Top 2 Earnings Picks For This Earnings Season
This morning, I woke up to the sound of pounding rain on the roof of my bus and a generator that made me decide to take the day off. Add in some flash flooding, a Wi-Fi signal riding on Starlink, and ...
Yesterday' Stock Market: What You Must Know!
Yesterday’s Stock Market Snapshot: Why Should You Care? If you took a glance at yesterday's stock market heatmap, you'd see a whole lot of red, with just a sprinkle of green. But what does that actual...
Tech drives gains: NVDA and AMD lead the charge while healthcare faces setbacks
📈 Technology Sector: Bolstered by Semiconductors The technology sector has emerged as the standout performer today, with semiconductor stocks taking center stage. Nvidia (NVDA) is soaring with a rema...
HSBC raises Glenmark Pharma share price target to Rs 2,275 on $1.9 billion AbbVie licensing deal
HSBC bullish on Glenmark Pharmaceuticals with a ‘Buy’ rating and has raised its target price to ₹2,275 per share, citing the company’s landmark out-licensing deal with global biopharma major AbbVie fo...
A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025
This isn't a buy list. It's a shortlist to help you speed up your research. We've included both U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull a...
Dividend Roundup: CVS Health, Procter & Gamble, AbbVie, Colgate-Palmolive, and more
Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades'
The investment landscape is shifting as companies across various sectors demonstrate resilience and innovation, prompting investors to reassess their portfolios. On CNBC's “Halftime Report Final Trade...
Glenmark Pharma jumps on unit's cancer licensing deal with AbbVie
Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.
Glenmark Pharma shares surge 10% after its subsidiary signs $700 million licensing deal with AbbVie for ISB 2001
Glenmark Pharmaceuticals witnessed a sharp 10% rise in its stock price during morning trade after announcing a major licensing agreement between its US-based innovation subsidiary, IGI Therapeutics SA...
Glenmark shares in focus after $700 million AbbVie deal for ISB 2001
Shares of Glenmark Pharmaceuticals are expected to remain in focus on Friday, July 11, after its subsidiary IGI Therapeutics SA signed a blockbuster licensing agreement with AbbVie worth up to $1.925 ...
Why Is AbbVie Stock Trading Higher On Thursday?
IGI Therapeutics SA , a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc ., and AbbVie Inc. (NYSE: ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lea...
Why Is AbbVie Stock Trading Higher On Thursday?
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investiga...
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
The Investment Committee give you their top stocks to watch for the second half.
AbbVie and Ichnos Glenmark sign licensing deal for trispecific antibody
India's Glenmark Pharma unit, Abbvie sign exclusive licensing pact
India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive global licensing agreement for IGI's cancer treatment, ISB 2...
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Glenmark Pharma’s subsidiary IGI Therapeutics signs $700 million licensing deal with AbbVie for ISB 2001
In a major development for the biopharma space, Glenmark Pharmaceuticals’ US-based innovation arm, IGI Therapeutics SA, has entered into an exclusive licensing agreement with global pharma giant AbbVi...
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NORTH CHICAGO, Ill. and NEW YORK , July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ...
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying h...
US major indices open mixed. Dow industrial average lower.S&P near unchanged.NASDAQ higher
Major US indices are opening mixed with the Dow industrial average lower: the S&P near unchanged, and the NASDAQ index higher the small-cap Russell 2000 is up modestly after falling -1.54% yesterday. ...